deucravacitinib (Sotyktu)
Jump to navigation
Jump to search
Indications
- moderate to severe plaque psoriasis
Contraindications
- avoid use with live virus vaccines
Dosage
Monitor
- serum triglycerides baseline & periodically
- liver function tests baseline & periodically
Adverse effects
- hypersensitivity reactions
- infactions including tuberculosis
- lymphomas
- elevated serum creatine kinase & rhabdomyolysis
- hypertriglyceridemia
- elevated serum ALT, serum AST
- drug adverse effects of tyrosine kinase inhibitor(s)
- drug adverse effects of janus kinase inhibitors
Mechanism of action
- tyrosine kinase-2 inhibitor (TYK2 inhibitor) thar inhibits signaling of IL-23, IL-12, & IFN-1, cytokines involved in the pathogenesis of autoimmune diseases[2]
More general terms
References
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION Sotyktu <TM> (deucravacitinib) tablets, for oral use https://packageinserts.bms.com/pi/pi_sotyktu.pdf
- ↑ 2.0 2.1 Splete H FDA Approves Oral TYK2 Inhibitor Deucravacitinib for Treating Psoriasis. Medscsape. Sept 12, 2022 https://www.medscape.com/viewarticle/980551
- ↑ Medscape: deucravacitinib (Rx) https://reference.medscape.com/drug/sotyktu-deucravacitinib-4000276